Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)

NSE:SUNPHARMA Revenue

Sun Pharmaceutical Industries had revenue of 153.00B INR in the quarter ending June 30, 2026, with 10.46% growth. This brings the company's total for the last twelve months to 599.11B, up 11.41% year-over-year. In the fiscal year ending March 31, 2026, Sun Pharmaceutical Industries had annual revenue of 584.62B with 11.19% growth. That makes Sun Pharmaceutical Industries the 2,189th largest company in the world by revenue and 59th in India.

• Revenue (ttm): 599.11B
• Revenue Growth: +11.41%
• P/S Ratio: 7.04
• Revenue / Employee: 12.75M
• Employees: 47,000
• Market Cap: 4.24T

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• India Formulations 192.90B 33.0%
• US Formulations 168.24B 28.8%
• Emerging Markets 111.86B 19.1%
• Rest of the World Formulations 85.68B 14.7%
• Active Pharmaceutical Ingredients (API) 21.85B 3.7%
• Other Operating 2.42B 0.4%
• Other Segment 1.65B 0.3%

By Geography

• India 196.94B 33.8%
• United States of America 176.20B 30.3%
• Emerging Markets 116.84B 20.1%
• Rest of The World 92.22B 15.8%

Fiscal year ended Mar 31, 2026 See the full NSE:SUNPHARMA breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2026	584.62B	58.84B	11.19%
Mar 31, 2025	525.78B	40.82B	8.42%
Mar 31, 2024	484.97B	46.11B	10.51%
Mar 31, 2023	438.86B	52.31B	13.53%
Mar 31, 2022	386.54B	51.56B	15.39%

Data Sources: S&P Global Market Intelligence and Fiscal.ai Last updated: Jul 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company. Revenue segment data is provided by Fiscal.ai.

Update frequency:

Quarterly

Last checked:

Oct 25, 2026

Data Sources Report a data error